Dan Gold’s hedge fund: Oncothyreon Inc (USA) (NASDAQ:ONTY) was just added to the equity portfolio of Daniel Gold’s hedge fund QVT Financial. In a filing with the Securities and Exchange Commission, QVT disclosed that it owns almost 3.7 million shares of Oncothyreon, the value of the stake amounting to $6.7 million. Through the acquisition, QVT holds about 5.8% of the company.
Oncothyreon is a company engaged in production of therapeutic products for the cancer treatment. The company expanded its net loss to $18 million for the second quarter, from last year’s amount of $8.1 million. At the same time, the company recently appointed the former Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Dr. Ted W. Love, to its Board of Directors.
Aside from QVT Financial, it is important to mention some other hedge funds who are bullish on Oncothyreon, according to our database. As follows, in the latest round of 13F filings, Israel Englander’s Millennium Management is the hedge fund with the second-largest stake, which involves 2.1 million shares. It is followed by First Eagle Investment Management, which disclosed ownership of 1.3 million shares, and Adage Capital Management, managed by Phill Gross and Robert Atchinson, which owned 950,000 shares at the end of the last quarter. Check back here for more updates on Dan Gold’s hedge fund.
There’s More to Carl Icahn’s Portfolio Than Just Apple and Dell
Warren Buffett Portfolio: How He’s Playing The Small-Caps
Value Investing Congress 2013: Small-Cap ‘Needles in a Haystack’ From Guy Gottfried